Mylan Granted US Patent Review of Allergan Eye-Care Drug
By

By
Mylan has been granted review of patents for Allergan’s blockbuster eye-care drug, Restasis (cyclosporine ophthalmic emulsion), by the US Patent & Trademark Office’s Patent Trial and Appeal Board (PTAB). The…

Perrigo Sells India API Manufacturing Plant to Strides Shasun
By

By
Perrigo has agreed to sell its entire shareholding in Perrigo API India to Strides Shasun, a Bangalore, India-based pharmaceutical company, for Indian rupee 1000 million ($14.8 million). The transaction includes…

Bayer Launches Stem Cell Therapy Company
By

By
Bayer and Versant Ventures, a San Francisco-based healthcare investment firm, have launched BlueRock Therapeutics, a regenerative medicine company that plans to develop induced pluripotent stem-cell therapies. To enable BlueRock Therapeutics’…

Sobi, Horizon Pharma in Europe Distribution Pact
By

By
Swedish Orphan Biovitrum (Sobi), a specialty healthcare company headquartered in Stockholm, Sweden, has entered into a five-year distribution agreement with Horizon Pharma, a biopharmaceutical company headquartered in Dublin, Ireland, for…

Purdue Pharma in Psoriasis Therapy Pact
By

By
Purdue Pharma, a Stamford, Connecticut-based pharmaceutical company, has signed a research collaboration, option, and license agreement with Exicure, a Skokie, Illinois-based clinical-stage biotechnology company, to discover and develop a treatment…

Sanofi Plans 20% Reduction in Diabetes, Cardiovascular Workforce
By

By
Sanofi has announced an approximate 20% reduction in staff at its US diabetes and cardiovascular business unit as part of a new realignment, the company said in a statement. Sanofi…

GSK Opens New Vaccines R&D Facility
By

By
GlaxoSmithKline (GSK) has opened a new global vaccines research and development (R&D) center in Rockville, Maryland and will be investing more than $50 million in the next two years to continue…

Almirall in $481-Million Skin-Disease Therapy Pact
By

By
Almirall, a Barcelona-based provider of medicines and medical devices, has formed a collaboration with Nuevolution A/S, a wholly owned subsidiary of Nuevolution AB, a small-molecule drug-discovery biotech company headquartered in…

Astellas Transfers Pain-Med Rights to Grunenthal
By

By
Astellas Pharma’s Astellas Pharma Europe business has agreed to transfer the exclusive rights for its pain medication, Qutenza (capsaicin 8% patch), in Europe, Middle East, and Africa to Grünenthal, an…

BMS Invests in Biologics Support, Makes US Site Changes
By

By
Bristol-Myers Squibb (BMS) has announced that it will make investments to support its biologics initiatives. The company will invest in the construction of a new research and development (R&D) building…